Abstract
The "bio drugs" allowed to treat diseases which have still today no remedies, diseases which are very expensive for the society. Unfortunately, needs of funds are huge and international markets are not well prepared yet. According to Henri Termeer, president of Genzyme Inc: "the healthcare market is focused on the cost reduction and not on the innovations' introduction". Companies will record improvements both in efficiency and in success rates along the value chain, and the average cost and time needed to bring a new drug to market will fall correspondingly. In fact, developing a new drug should become considerably less unpredictable and much less expensive. Those that embrace the revolution most boldly could potentially halve the cost and time it takes to make a new drug, if they meet certain challenges successfully. As in any revolution, the risks for a firm of standing aside may be greater than those of getting involved. The revolution is real, and will leave no one untouched
